Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a reversible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamous cell carcinoma of the lung.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Aug 2015

Volume: 16

Issue: 8

Affiliations

[1 ] Gustave Roussy Cancer Campus and University Paris-Sud, Paris, France. Electronic address: Jean-Charles.Soria@gustaveroussy.fr.

[2 ] Medical Oncology Department, Vall d' Hebron University Hospital, Vall d' Hebron Institute of Oncology, Barcelona, Spain.

[3 ] Hospital Carlos Haya, Malaga, Spain.

[4 ] Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

[5 ] Athens School of Medicine, Athens, Greece.

[6 ] Chungbuk National University College of Medicine, Cheongju, South Korea.

[7 ] Ege University Faculty of Medicine, Izmir, Turkey.

[8 ] Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.

[9 ] First Hospital Affiliated to Jilin University, Jilin, China.

[10 ] Hospital Lozano Blesa, Zaragoza, Spain.

[11 ] Izmir Chest Diseases Research Hospital, Izmir, Turkey.

[12 ] Istituto Nazionale Tumori "Fondazione G Pascale"-IRCCS, Naples, Italy.

[13 ] Department of Medicine, Ulsan University Hospital, Ulsan, South Korea.

[14 ] University Hospital, Bologna, Italy.

[15 ] Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.

[16 ] Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.

[17 ] Division of Medical Oncology, University of Ottawa, Ottawa, ON, Canada.

Article

Publisher Item ID: S1470-2045(15)00006-6

DOI: 10.1016/S1470-2045(15)00006-6

PubMed ID: 26156651

SO-VID: fcb7f9e4-f8be-42b9-bbf0-d237c0c770ef

History

Data availability:

Comments

Comment on this article

scite_

Cited by 168

See all cited by

- Version 1